Document Detail


Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants.
MedLine Citation:
PMID:  18956993     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY OBJECTIVES: To evaluate the frequency and severity of retinopathy of prematurity in extremely low-birth-weight (ELBW) infants who received recombinant human erythropoietin (rHuEPO), and to compare the frequency of blood cell transfusions these infants required with a matched control group who did not receive rHuEPO. DESIGN: Retrospective cohort analysis. SETTING: Level III neonatal intensive care unit in a large academic medical center. PATIENTS: One hundred thirty-eight ELBW infants who received rHuEPO and 138 ELBW infants who did not (control group) but who were matched by birth weight, gestational age, sex, and year of birth and who survived to the first ophthalmologic examination. MEASUREMENTS AND MAIN RESULTS: The rHuEPO was started before the 8th day of life in 115 (83%) of the 138 infants. Stages III-V retinopathy of prematurity occurred with similar frequency in both groups of infants (rHuEPO group 19% [26 infants] vs control group 20% [27 infants], p>0.05). Infants in the rHuEPO group received fewer transfusions on average during their hospitalization compared with those in the control group (4.2 vs 6.1 transfusions, p<0.01). CONCLUSION: Use of rHuEPO for prevention or treatment of anemia of prematurity in ELBW infants does not increase the frequency of severe retinopathy of prematurity and reduces the number of transfusions.
Authors:
Jacqueline K Schneider; Debra K Gardner; Leandro Cordero
Related Documents :
659573 - Rubella virus hemagglutination with human and animal erythrocytes: effect of age and tr...
22931293 - Comparison of the transcutaneous bilirubinometers bilicheck and minolta jm-103 in prete...
3899343 - Role of carnitine during development.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pharmacotherapy     Volume:  28     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-29     Completed Date:  2009-01-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1335-40     Citation Subset:  IM    
Affiliation:
Department of Pharmacy Services, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA. Jacqueline.Schneider@nationwidechildrens.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / complications,  drug therapy
Birth Weight
Blood Transfusion / statistics & numerical data
Cohort Studies
Erythropoietin, Recombinant / adverse effects*,  therapeutic use
Female
Gestational Age
Humans
Infant, Extremely Low Birth Weight / physiology*
Infant, Newborn
Male
Pregnancy
Pregnancy Outcome
Retinopathy of Prematurity / complications*
Retrospective Studies
Risk Assessment
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk of adverse gastrointestinal events from inhaled corticosteroids.
Next Document:  Influence of patient characteristics on success of ambulatory blood pressure monitoring.